William Mr. Burke Sells 14,571 Shares of AxoGen (NASDAQ:AXGN) Stock

Key Points

• Director William Mr. Burke sold 14,571 shares of AxoGen (NASDAQ: AXGN) stock on October 3rd, reducing his ownership by 86.40% and generating a total of $265,337.91.
• AxoGen's current stock price is $17.16, showing a decrease of $0.72 during recent trading, with a market capitalization of approximately $789.53 million.
• AxoGen has a consensus rating of "Moderate Buy" from analysts, with a price target of $25.75, despite having mixed ratings from various research reports.

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director William Mr. Burke sold 14,571 shares of the business's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $18.21, for a total value of $265,337.91. Following the sale, the director owned 2,293 shares of the company's stock, valued at approximately $41,755.53. This represents a 86.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

AxoGen Stock Performance

Shares of AxoGen stock traded down $0.72 during trading hours on Monday, reaching $17.16. 799,560 shares of the stock traded hands, compared to its average volume of 841,431. The company has a 50 day moving average price of $15.68 and a 200 day moving average price of $14.12. The firm has a market capitalization of $789.53 million, a price-to-earnings ratio of -171.58 and a beta of 1.04. AxoGen, Inc. has a one year low of $9.22 and a one year high of $21.00. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59.

Analyst Ratings Changes

AXGN has been the subject of a number of recent research reports. HC Wainwright assumed coverage on AxoGen in a research note on Tuesday, September 30th. They set a "buy" rating and a $25.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of AxoGen in a research note on Saturday, September 27th. Finally, Wall Street Zen upgraded AxoGen from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, AxoGen currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.75.

Institutional Trading of AxoGen

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its position in AxoGen by 189.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider's stock worth $55,000 after buying an additional 3,327 shares during the last quarter. AlphaQuest LLC grew its position in AxoGen by 882.2% in the 2nd quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider's stock valued at $68,000 after acquiring an additional 5,637 shares during the last quarter. State of Wyoming bought a new position in AxoGen in the 2nd quarter valued at $69,000. PNC Financial Services Group Inc. grew its position in AxoGen by 120.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,077 shares of the medical equipment provider's stock valued at $88,000 after acquiring an additional 4,409 shares during the last quarter. Finally, Fifth Third Bancorp bought a new position in AxoGen in the 1st quarter valued at $92,000. 80.29% of the stock is currently owned by institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.